Wet age-related macular degeneration (wet AMD) has a profound impact on patient quality of life and imposes a considerable financial burden on healthcare systems. It is estimated that approximately 70% of patients with wet AMD will experience severe vision loss within two years of receiving the diagnosis. There is a compelling need for new therapies that improve visual outcomes and lower the burden of care by reducing the need for repeated monthly injections and eliminating or extending the period between treatments.
SalutarisMD is developing a minimally invasive ophthalmic technology for the treatment of Wet AMD. The technology delivers a single dose of brachytherapy. Brachytherapy involves the placement of a therapeutic radioisotope inside or next to the area requiring treatment and has shown utility in the clinical management of many diseases.
The SalutarisMD device is designed for use in an outpatient setting under local anaesthesia. Proprietary technology allows the retina surgeon to employ an extraocular (outside the eye), retrobulbar (behind the eye) placement of the device cannula. This approach is termed the “sub-Tenon” approach. The cannula is positioned over the globe of the eye, between the sclera and Tenon’s capsule. A fibre optic light source at the tip of the cannula is used to position the cannula behind the eye. The retina surgeon locates the device by indirect ophthalmoscopic visualisation of the transilluminated light. With the light placed over the lesion, a targeted radiation dose can be delivered directly to the choroidal neovascularisation. The device containing the source is then removed. Total procedure time is approximately 15 minutes. Nothing is left behind in the patient and the intraocular space is never violated.
SalutarisMD believes that this method has the advantage of avoiding more invasive surgical techniques, and delivers localised tissue irradiation performed under the direct care and expertise of a retina specialist. The SalutarisMD device is designed as a practical procedure that can be performed in the same clinical environment as current anti-VEGF injections.
Watch our presentations at Ophthalmology Futures here.
Watch our presentation at OIS here.
Read a recent peer-reviewed medical journal review article “Brachytherapy in Neovascular AMD” here.